ESC 2020: Commentary on the DAPA-CKD Study

Published: 22 Sep 2020

  • Views:

    Views Icon 422
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

Dr Giuseppe Galati (San Raffaele Scientific Institute, Milan, IT) discusses the DAPA-CKD study that was presented at ESC 2020. 

This study evaluated the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.

Recorded remotely from Milan, 2020. 

Recording Editor: Natascha Wienand
Editor: Mirjam Boros